首页 > 最新文献

Value in health regional issues最新文献

英文 中文
Cost Analysis of Epilepsy Healthcare in Adults: A Direct Cost Estimate From a Colombian Perspective 成人癫痫保健的成本分析:从哥伦比亚的角度进行直接成本估算。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-11 DOI: 10.1016/j.vhri.2024.101074
Maritza Alegría-Muñoz RN , César A. Buitrago-Guzmán MD , Camilo Espinosa-Jovel MD , Jorge L. Ramírez-Molina MD , Mateo Enciso-Zuluaga MD , Oscar A. Escobar MD , Gina Montaño-Padilla MD , Carmelo J. Espinosa-Almanza MD , Julieth Martínez MD , Cristian E. Navarro MD, MSc, PhD
<div><h3>Objetivos</h3><div>Estimar los costos directos sanitarios que genera la atención ambulatoria y hospitalaria de los adultos con epilepsia en Colombia desde la perspectiva del sistema de salud.</div></div><div><h3>Métodos</h3><div>Análisis de costos a partir de un caso base, que incluyó los costos médicos directos relacionados con el diagnóstico, con el seguimiento, con el tratamiento farmacológico y quirúrgico, y con la atención intrahospitalaria del <em>status epilepticus (SE)</em>. Se llevó a cabo un panel Delphi para la identificación y la cuantificación de los eventos generadores de costos. La valoración monetaria se estimó usando las bases de datos y manuales tarifarios oficiales disponibles en Colombia. Se obtuvo la distribución de los costos utilizando el método de <em>bootstraping.</em> Se ejecutaron dos análisis de sensibilidad determinísticos de una vía.</div></div><div><h3>Resultados</h3><div>El costo total anual de un paciente adulto con epilepsia sin considerar atención hospitalaria por SE es de US dollars $2416.31. Si se incluye al menos una estancia promedio de 8 días en unidad de cuidado intensivo (UCI) para tratar a un paciente con SE, el costo total anual se incrementa a $61 567.72. El costo total de la cirugía resectiva es de $14 894.44, y del implante del estimulador de nervio vago es de $26 565.86.</div></div><div><h3>Conclusión</h3><div>La epilepsia en adultos genera una carga económica para el sistema de salud colombiano similar a la de otros países de ingresos medianos-altos. La fracción principal del gasto la tiene la estancia en UCI, menos recursos económicos se requerirían si los pacientes logran un mejor control de la enfermedad.</div></div><div><h3>Objectives</h3><div>To estimate the direct healthcare costs related to outpatient care and hospital stays for adults with epilepsy in the context of the Colombian healthcare system.</div></div><div><h3>Methods</h3><div>A cost analysis was conducted from a base case, which included direct medical costs related to diagnosis, follow-up, pharmacological and surgical treatment, and in-hospital care for status epilepticus. A Delphi panel was carried out to identify and quantify cost-generating events. The monetary valuation was estimated using official databases and tariff manuals available in Colombia. The cost distribution was obtained using the bootstrapping method. Two one-way deterministic sensitivity analyses were performed.</div></div><div><h3>Results</h3><div>The total annual cost of an adult patient with epilepsy without including hospital stays is US dollars $2416.31. If at least 1 intensive care unit stay (8-day average) is included to treat a patient with status epilepticus, the total annual cost increases to $61 567.72. The total cost of resective surgery is $14 894.44, and the vagus nerve stimulation implant costs $26 565.86.</div></div><div><h3>Conclusions</h3><div>Epilepsy in adults represents a significant economic burden for the Colombian healthcare syst
目的:估计在哥伦比亚医疗保健系统的背景下,与成人癫痫患者门诊护理和住院有关的直接医疗保健费用。方法:从一个基本病例开始进行成本分析,包括与癫痫持续状态的诊断、随访、药物和手术治疗以及住院护理相关的直接医疗费用。进行了德尔菲小组来确定和量化产生成本的事件。货币估值是根据哥伦比亚现有的官方数据库和关税手册估计的。采用自举法得到了成本分布。进行了两次单向确定性敏感性分析。结果:一名成人癫痫患者不包括住院时间的年总费用为2416.31美元。如果包括至少1次重症监护病房(平均8天)来治疗癫痫持续状态患者,则每年的总费用增加到61 567.72美元。切除手术的总费用为14 894.44美元,迷走神经刺激植入物为26 565.86美元。结论:成人癫痫是哥伦比亚卫生保健系统的重大经济负担,与其他中高收入国家相当。大部分支出用于重症监护病房,如果患者能更好地控制疾病,所需的财政资源就会减少。
{"title":"Cost Analysis of Epilepsy Healthcare in Adults: A Direct Cost Estimate From a Colombian Perspective","authors":"Maritza Alegría-Muñoz RN ,&nbsp;César A. Buitrago-Guzmán MD ,&nbsp;Camilo Espinosa-Jovel MD ,&nbsp;Jorge L. Ramírez-Molina MD ,&nbsp;Mateo Enciso-Zuluaga MD ,&nbsp;Oscar A. Escobar MD ,&nbsp;Gina Montaño-Padilla MD ,&nbsp;Carmelo J. Espinosa-Almanza MD ,&nbsp;Julieth Martínez MD ,&nbsp;Cristian E. Navarro MD, MSc, PhD","doi":"10.1016/j.vhri.2024.101074","DOIUrl":"10.1016/j.vhri.2024.101074","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objetivos&lt;/h3&gt;&lt;div&gt;Estimar los costos directos sanitarios que genera la atención ambulatoria y hospitalaria de los adultos con epilepsia en Colombia desde la perspectiva del sistema de salud.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Métodos&lt;/h3&gt;&lt;div&gt;Análisis de costos a partir de un caso base, que incluyó los costos médicos directos relacionados con el diagnóstico, con el seguimiento, con el tratamiento farmacológico y quirúrgico, y con la atención intrahospitalaria del &lt;em&gt;status epilepticus (SE)&lt;/em&gt;. Se llevó a cabo un panel Delphi para la identificación y la cuantificación de los eventos generadores de costos. La valoración monetaria se estimó usando las bases de datos y manuales tarifarios oficiales disponibles en Colombia. Se obtuvo la distribución de los costos utilizando el método de &lt;em&gt;bootstraping.&lt;/em&gt; Se ejecutaron dos análisis de sensibilidad determinísticos de una vía.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Resultados&lt;/h3&gt;&lt;div&gt;El costo total anual de un paciente adulto con epilepsia sin considerar atención hospitalaria por SE es de US dollars $2416.31. Si se incluye al menos una estancia promedio de 8 días en unidad de cuidado intensivo (UCI) para tratar a un paciente con SE, el costo total anual se incrementa a $61 567.72. El costo total de la cirugía resectiva es de $14 894.44, y del implante del estimulador de nervio vago es de $26 565.86.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusión&lt;/h3&gt;&lt;div&gt;La epilepsia en adultos genera una carga económica para el sistema de salud colombiano similar a la de otros países de ingresos medianos-altos. La fracción principal del gasto la tiene la estancia en UCI, menos recursos económicos se requerirían si los pacientes logran un mejor control de la enfermedad.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To estimate the direct healthcare costs related to outpatient care and hospital stays for adults with epilepsy in the context of the Colombian healthcare system.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A cost analysis was conducted from a base case, which included direct medical costs related to diagnosis, follow-up, pharmacological and surgical treatment, and in-hospital care for status epilepticus. A Delphi panel was carried out to identify and quantify cost-generating events. The monetary valuation was estimated using official databases and tariff manuals available in Colombia. The cost distribution was obtained using the bootstrapping method. Two one-way deterministic sensitivity analyses were performed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The total annual cost of an adult patient with epilepsy without including hospital stays is US dollars $2416.31. If at least 1 intensive care unit stay (8-day average) is included to treat a patient with status epilepticus, the total annual cost increases to $61 567.72. The total cost of resective surgery is $14 894.44, and the vagus nerve stimulation implant costs $26 565.86.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Epilepsy in adults represents a significant economic burden for the Colombian healthcare syst","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101074"},"PeriodicalIF":1.4,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Pain—A Global Problem Demanding Local Evidence and Guidelines 慢性疼痛——一个需要当地证据和指南的全球性问题。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-01 DOI: 10.1016/j.vhri.2024.101069
Rafael Pinedo-Villanueva BA, MSc, PhD , Manuel A. Espinoza MD, MSc, PhD
{"title":"Chronic Pain—A Global Problem Demanding Local Evidence and Guidelines","authors":"Rafael Pinedo-Villanueva BA, MSc, PhD ,&nbsp;Manuel A. Espinoza MD, MSc, PhD","doi":"10.1016/j.vhri.2024.101069","DOIUrl":"10.1016/j.vhri.2024.101069","url":null,"abstract":"","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"45 ","pages":"Article 101069"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Burden of Alzheimer’s Disease and Its Costs to a Healthcare System in a Large Population in Brazil 阿尔茨海默病的负担及其对巴西大量人口的医疗保健系统的成本。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2025-01-01 DOI: 10.1016/j.vhri.2024.101064
Ana Carolina Vilarinho PhD, Rhainer Guillermo Ferreira PhD

Objectives

In Brazil, cases of Alzheimer's disease (AD) are particularly prevalent in the southeastern region, including Minas Gerais, the largest state in the area. This study aimed to estimate the disease burden and healthcare costs from 2018 to 2022.

Methods

Data on life expectancy, human development index, population size, and gross domestic product per capita were extracted to calculate disability-adjusted life-years (DALYs). Hospital admission data for AD were obtained from the Brazilian Unified Health System Department of Informatics (DATASUS) database, including the number of cases, deaths, age-specific data, and treatment costs. These variables, along with health, social, and environmental data, were processed to create risk factor layers, and the mean cost per DALY was calculated. Generalized estimating equation models were used to analyze the relationship between DALYs and various predictors, controlling for spatial autocorrelation. Maps were created to visualize the distribution of DALYs and cost per DALY.

Results

There were 323 221 deaths from AD in Brazil, with cities averaging 3.61 deaths (range 1-73) and 5.43 hospitalizations (range 1-91) annually. The mean cost per city over these years was $9935.87 (range $44.22 to $787 307.93). In Minas Gerais, significant predictors of the estimated burden of AD include the percentage of the population aged 65 years and older, the human development index, and the prevalence of cardiovascular diseases. DALYs were higher than observed, indicating potential underreporting and insufficient resource allocation for AD treatment and prevention.

Conclusions

These results emphasize the need for region-specific policies and strategies to address the AD burden effectively. Policy makers should use this information to improve planning and allocate resources appropriately for treatment and prevention.
目的:在巴西,阿尔茨海默病(AD)病例在东南部地区特别普遍,包括该地区最大的州米纳斯吉拉斯州。本研究旨在估计2018年至2022年的疾病负担和医疗费用。方法:提取预期寿命、人类发展指数、人口规模和人均国内生产总值等数据,计算伤残调整生命年(DALYs)。阿尔茨海默病的住院数据来自巴西统一卫生系统信息部(DATASUS)数据库,包括病例数、死亡人数、特定年龄数据和治疗费用。对这些变量以及健康、社会和环境数据进行处理,形成风险因素层,并计算每个DALY的平均成本。采用广义估计方程模型分析DALYs与各种预测因子之间的关系,控制空间自相关。我们制作了图表来可视化DALY的分布和每个DALY的成本。结果:巴西有323221例AD死亡,城市平均每年有3.61例死亡(范围1-73),5.43例住院(范围1-91)。这些年来,每个城市的平均成本为9935.87美元(44.22美元至787 307.93美元)。在米纳斯吉拉斯州,阿尔茨海默病估计负担的重要预测指标包括65岁及以上人口的百分比、人类发展指数和心血管疾病的患病率。DALYs高于观察值,表明潜在的低报和用于AD治疗和预防的资源分配不足。结论:这些结果强调需要制定针对特定区域的政策和战略来有效解决AD负担。决策者应该利用这些信息来改进规划,并适当地为治疗和预防分配资源。
{"title":"The Burden of Alzheimer’s Disease and Its Costs to a Healthcare System in a Large Population in Brazil","authors":"Ana Carolina Vilarinho PhD,&nbsp;Rhainer Guillermo Ferreira PhD","doi":"10.1016/j.vhri.2024.101064","DOIUrl":"10.1016/j.vhri.2024.101064","url":null,"abstract":"<div><h3>Objectives</h3><div>In Brazil, cases of Alzheimer's disease (AD) are particularly prevalent in the southeastern region, including Minas Gerais, the largest state in the area. This study aimed to estimate the disease burden and healthcare costs from 2018 to 2022.</div></div><div><h3>Methods</h3><div>Data on life expectancy, human development index, population size, and gross domestic product per capita were extracted to calculate disability-adjusted life-years (DALYs). Hospital admission data for AD were obtained from the Brazilian Unified Health System Department of Informatics (DATASUS) database, including the number of cases, deaths, age-specific data, and treatment costs. These variables, along with health, social, and environmental data, were processed to create risk factor layers, and the mean cost per DALY was calculated. Generalized estimating equation models were used to analyze the relationship between DALYs and various predictors, controlling for spatial autocorrelation. Maps were created to visualize the distribution of DALYs and cost per DALY.</div></div><div><h3>Results</h3><div>There were 323 221 deaths from AD in Brazil, with cities averaging 3.61 deaths (range 1-73) and 5.43 hospitalizations (range 1-91) annually. The mean cost per city over these years was $9935.87 (range $44.22 to $787 307.93). In Minas Gerais, significant predictors of the estimated burden of AD include the percentage of the population aged 65 years and older, the human development index, and the prevalence of cardiovascular diseases. DALYs were higher than observed, indicating potential underreporting and insufficient resource allocation for AD treatment and prevention.</div></div><div><h3>Conclusions</h3><div>These results emphasize the need for region-specific policies and strategies to address the AD burden effectively. Policy makers should use this information to improve planning and allocate resources appropriately for treatment and prevention.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"45 ","pages":"Article 101064"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing the Travel Burden for Patients to Access Specialized Medicines in Paraná, Brazil. 在巴西帕拉纳岛减轻患者获得专业药物的旅行负担。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-12-23 DOI: 10.1016/j.vhri.2024.101065
Paula Rossignoli, Roberto Pontarolo, Fernando Fernandez-Llimos

Objectives: This study aimed to evaluate the potential reduction in distance and travel time with a hypothetical municipal distribution of specialized component medicines in the state of Paraná.

Methods: This was a cross-sectional study. Distances and travel times from all the 1025 residential locations in the state of Paraná to dispensing pharmacies were calculated in 2 different models: centralized model with drugs dispensed in the 22 state-owned pharmacies and decentralized model with drugs dispensed in the 399 municipal pharmacies. Road routes were calculated using the Google Maps Distance Matrix API and Euclidean distance using the haversine formula for the southern hemisphere. A sinuosity index was computed by the quotient between these 2 distances. Differences were evaluated through bivariate analyses and effect size measures were reported.

Results: In the centralized model, the mean distance to the pharmacy was 59.5 km (SD 34.1), with a travel time of 1.0 hour (SD 0.5) and 579 residential locations (56.7%) more than 50 km away from the pharmacy, 286 (28.0%) between 25 and 50 km, and 156 (15.3%) less than 25 km. In the decentralized model, the mean distance was 10.8 km (SD 16.6), with a travel time of 0.2 hours (SD 0.3) and 14 locations (1.4%) more than 50 km away from the pharmacy, 96 (9.4%) between 25 and 50 km, and 911 (89.2%) less than 25 km. The decentralized model significantly reduced the sinuosity index.

Conclusions: Implementing a decentralized dispensing of the specialized component drugs in the state of Paraná would produce a significant reduction in distance and travel time for patients enhancing drug accessibility.

目的:本研究旨在评估潜在的距离和旅行时间的减少与一个假设的城市分布的专业成分药物在帕拉纳州。方法:采用横断面研究。采用集中式模式(22家国有药店)和分散式模式(399家市属药店)两种不同的模式计算从帕拉南州1025个居民点到调剂药店的距离和出行时间。道路路线计算使用谷歌地图距离矩阵API和欧几里得距离使用哈弗斯公式南半球。通过这两个距离之间的商计算出一个曲度指数。通过双变量分析和效应量测量来评估差异。结果:集中式模型中,居民到药店的平均距离为59.5 km (SD为34.1),出行时间为1.0 h (SD为0.5);579个居民点(56.7%)距离药店大于50 km, 286个居民点(28.0%)在25 ~ 50 km之间,156个居民点(15.3%)距离药店小于25 km。在分散式模型中,平均距离为10.8 km (SD为16.6),出行时间为0.2 h (SD为0.3),距离药店超过50 km的有14个(1.4%),距离25 ~ 50 km的有96个(9.4%),距离药店小于25 km的有911个(89.2%)。分散模型显著降低了弯曲度指数。结论:在帕拉纳州实施分散式专业成分药的配药,将大大减少患者的路程和出行时间,提高药品可及性。
{"title":"Reducing the Travel Burden for Patients to Access Specialized Medicines in Paraná, Brazil.","authors":"Paula Rossignoli, Roberto Pontarolo, Fernando Fernandez-Llimos","doi":"10.1016/j.vhri.2024.101065","DOIUrl":"10.1016/j.vhri.2024.101065","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the potential reduction in distance and travel time with a hypothetical municipal distribution of specialized component medicines in the state of Paraná.</p><p><strong>Methods: </strong>This was a cross-sectional study. Distances and travel times from all the 1025 residential locations in the state of Paraná to dispensing pharmacies were calculated in 2 different models: centralized model with drugs dispensed in the 22 state-owned pharmacies and decentralized model with drugs dispensed in the 399 municipal pharmacies. Road routes were calculated using the Google Maps Distance Matrix API and Euclidean distance using the haversine formula for the southern hemisphere. A sinuosity index was computed by the quotient between these 2 distances. Differences were evaluated through bivariate analyses and effect size measures were reported.</p><p><strong>Results: </strong>In the centralized model, the mean distance to the pharmacy was 59.5 km (SD 34.1), with a travel time of 1.0 hour (SD 0.5) and 579 residential locations (56.7%) more than 50 km away from the pharmacy, 286 (28.0%) between 25 and 50 km, and 156 (15.3%) less than 25 km. In the decentralized model, the mean distance was 10.8 km (SD 16.6), with a travel time of 0.2 hours (SD 0.3) and 14 locations (1.4%) more than 50 km away from the pharmacy, 96 (9.4%) between 25 and 50 km, and 911 (89.2%) less than 25 km. The decentralized model significantly reduced the sinuosity index.</p><p><strong>Conclusions: </strong>Implementing a decentralized dispensing of the specialized component drugs in the state of Paraná would produce a significant reduction in distance and travel time for patients enhancing drug accessibility.</p>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":" ","pages":"101065"},"PeriodicalIF":1.4,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Aerial Logistics for Immunization: A Model-Based Evaluation of Centralized Storage and Drone Delivery of Vaccines in Ghana Using Empirical Data 航空物流免疫的成本效益:基于模型的评估集中储存和无人机交付疫苗在加纳使用经验数据。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-12-21 DOI: 10.1016/j.vhri.2024.101066
Maria J. Ospina-Fadul MSc , Pedro Kremer PhD , Scott E. Stevens MSc , Florence Haruna MPhil , Marion Okoh-Owusu MD , Godfred K. Sarpong MPH , Kingsley Osei-Kwakye MD , Billy Joshua BSc , Osei Sakyi MPH

Objectives

In mid-2020, the Ghana Health Service introduced Zipline’s aerial logistics (centralized storage and delivery by drones) in the Western North Region to enhance health supply chain resilience. This intervention led to improved vaccination coverage in high-utilization districts. This study assessed the cost-effectiveness of aerial logistics as an intervention to improve immunization coverage.

Methods

An attack rate model, adjusted for vaccination coverage and vaccine efficacy, was used to estimate disease incidence among vaccinated and unvaccinated populations, focusing on 17 022 infants. Incremental cost-effectiveness ratios of US dollar per averted disability-adjusted life-year (DALY) were evaluated from societal and government perspectives, using real-world operations data. Probabilistic sensitivity analysis was performed using Monte Carlo simulations.

Results

In 2021, aerial logistics averted 688 disease cases. Incremental cost-effectiveness ratios were $41 and $58 per averted DALY from the societal and government perspectives, respectively. The intervention was cost-saving when at least 20% of vaccines delivered by aerial logistics replaced those that would have been delivered by ground transportation, with potential government savings of up to $250 per averted DALY. Sensitivity analysis confirmed the robustness of these findings.

Conclusions

Under conservative assumptions, aerial logistics was a highly cost-effective intervention to increase immunization coverage. The intervention was cost-saving even with low levels of replacement of traditional last mile delivery. These findings support expanding aerial logistics within the national immunization program and have significant implications for other low- and middle-income countries seeking cost-effective health supply chain solutions.
目标:2020年年中,加纳卫生服务局在西北地区引入Zipline的空中物流(集中储存和无人机配送),以增强卫生供应链的弹性。这一干预措施提高了疫苗使用率高的地区的疫苗接种覆盖率。本研究评估了空运物流作为提高免疫覆盖率的干预措施的成本效益。方法:采用发病率模型,对疫苗接种覆盖率和疫苗效力进行调整,估计接种疫苗和未接种疫苗人群的疾病发病率,重点关注17 022名婴儿。使用实际操作数据,从社会和政府的角度评估了每个避免残疾调整生命年(DALY)的增量成本效益比。采用蒙特卡罗模拟方法进行了概率敏感性分析。结果:2021年,航空物流共避免疾病病例688例。从社会和政府的角度来看,每避免DALY的增量成本效益比率分别为41美元和58美元。这一干预措施节省了成本,至少20%的疫苗由航空物流运送,取代了原本可以由地面运输运送的疫苗,每避免一次伤残调整年,政府可能节省高达250美元。敏感性分析证实了这些发现的稳健性。结论:在保守假设下,航空物流是一种高成本效益的提高免疫覆盖率的干预措施。即使对传统的最后一英里配送的替代水平很低,这种干预措施也节省了成本。这些发现支持在国家免疫规划范围内扩大航空物流,并对寻求具有成本效益的卫生供应链解决方案的其他低收入和中等收入国家具有重大意义。
{"title":"Cost-Effectiveness of Aerial Logistics for Immunization: A Model-Based Evaluation of Centralized Storage and Drone Delivery of Vaccines in Ghana Using Empirical Data","authors":"Maria J. Ospina-Fadul MSc ,&nbsp;Pedro Kremer PhD ,&nbsp;Scott E. Stevens MSc ,&nbsp;Florence Haruna MPhil ,&nbsp;Marion Okoh-Owusu MD ,&nbsp;Godfred K. Sarpong MPH ,&nbsp;Kingsley Osei-Kwakye MD ,&nbsp;Billy Joshua BSc ,&nbsp;Osei Sakyi MPH","doi":"10.1016/j.vhri.2024.101066","DOIUrl":"10.1016/j.vhri.2024.101066","url":null,"abstract":"<div><h3>Objectives</h3><div>In mid-2020, the Ghana Health Service introduced Zipline’s aerial logistics (centralized storage and delivery by drones) in the Western North Region to enhance health supply chain resilience. This intervention led to improved vaccination coverage in high-utilization districts. This study assessed the cost-effectiveness of aerial logistics as an intervention to improve immunization coverage.</div></div><div><h3>Methods</h3><div>An attack rate model, adjusted for vaccination coverage and vaccine efficacy, was used to estimate disease incidence among vaccinated and unvaccinated populations, focusing on 17 022 infants. Incremental cost-effectiveness ratios of US dollar per averted disability-adjusted life-year (DALY) were evaluated from societal and government perspectives, using real-world operations data. Probabilistic sensitivity analysis was performed using Monte Carlo simulations.</div></div><div><h3>Results</h3><div>In 2021, aerial logistics averted 688 disease cases. Incremental cost-effectiveness ratios were $41 and $58 per averted DALY from the societal and government perspectives, respectively. The intervention was cost-saving when at least 20% of vaccines delivered by aerial logistics replaced those that would have been delivered by ground transportation, with potential government savings of up to $250 per averted DALY. Sensitivity analysis confirmed the robustness of these findings.</div></div><div><h3>Conclusions</h3><div>Under conservative assumptions, aerial logistics was a highly cost-effective intervention to increase immunization coverage. The intervention was cost-saving even with low levels of replacement of traditional last mile delivery. These findings support expanding aerial logistics within the national immunization program and have significant implications for other low- and middle-income countries seeking cost-effective health supply chain solutions.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101066"},"PeriodicalIF":1.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Real-World Evidence for Health Technology Assessment in Asia: Suggested Typology and Scoping Review 在亚洲使用真实世界证据进行卫生技术评估:建议的类型和范围审查。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-12-15 DOI: 10.1016/j.vhri.2024.101068
Ryan R. Nugraha MD, MPH , Arie Rahadi PhD , Christian Suharlim MD, MPH

Objectives

This study aimed to provide the typology of real-world evidence (RWE) and challenges associated with improving the use of RWE in Asian countries.

Methods

This article is divided into 2 subsections. First, a narrative review was conducted to classify RWE based on available real-world data. This method was also used to develop a typology of RWE, particularly considering the nature of the data, the potential evidence generated, and the integration methods into health technology assessment (HTA). Finally, a scoping review was undertaken to identify and filter studies focusing on the implementation of RWE in Asia.

Results

The use of RWE is associated with many caveats, and therefore, its use in Asia is particularly limited. Based on the narrative review, RWE is divided into 3 broad categories: macro-, meso-, and micro-RWE; each represents a different quality of evidence and range of use as evidence for HTA. Although typology helps with consolidating RWE choices for supporting HTA decision making, challenges still persist in using it for HTA purposes. Institutional support, technical capacity, and infrastructure, including data-related issues, may hinder progress in improving the RWE ecosystem for HTA in Asia.

Conclusions

RWE is a helpful tool that can assist in decision making, especially in reimbursement-related decisions. Although knowing facets of RWE helps in choosing appropriate evidence to assist in policy making, challenges associated with its implementation, especially in the Asian context, need to be anticipated.
目的:本研究旨在提供真实世界证据(RWE)的类型以及与改善亚洲国家RWE使用相关的挑战。方法:本文分为两部分。首先,基于现有的真实世界数据,对RWE进行了叙述性的分类。该方法还用于制定RWE的类型,特别是考虑到数据的性质、产生的潜在证据以及将方法整合到卫生技术评估(HTA)中。最后,进行了范围审查,以确定和筛选侧重于在亚洲实施RWE的研究。结果:RWE的使用与许多警告有关,因此,它在亚洲的使用特别有限。在叙述回顾的基础上,RWE分为三大类:宏观、中观和微观RWE;每一种都代表了不同的证据质量和作为HTA证据的使用范围。尽管类型学有助于巩固RWE选择以支持HTA决策制定,但在将其用于HTA目的方面仍然存在挑战。机构支持、技术能力和基础设施,包括与数据相关的问题,可能会阻碍改善亚洲HTA RWE生态系统的进展。结论:RWE是一个有用的工具,可以帮助决策,特别是在报销相关的决策。虽然了解RWE的各个方面有助于选择适当的证据来协助制定政策,但需要预测与实施RWE相关的挑战,特别是在亚洲背景下。
{"title":"Using Real-World Evidence for Health Technology Assessment in Asia: Suggested Typology and Scoping Review","authors":"Ryan R. Nugraha MD, MPH ,&nbsp;Arie Rahadi PhD ,&nbsp;Christian Suharlim MD, MPH","doi":"10.1016/j.vhri.2024.101068","DOIUrl":"10.1016/j.vhri.2024.101068","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to provide the typology of real-world evidence (RWE) and challenges associated with improving the use of RWE in Asian countries.</div></div><div><h3>Methods</h3><div>This article is divided into 2 subsections. First, a narrative review was conducted to classify RWE based on available real-world data. This method was also used to develop a typology of RWE, particularly considering the nature of the data, the potential evidence generated, and the integration methods into health technology assessment (HTA). Finally, a scoping review was undertaken to identify and filter studies focusing on the implementation of RWE in Asia.</div></div><div><h3>Results</h3><div>The use of RWE is associated with many caveats, and therefore, its use in Asia is particularly limited. Based on the narrative review, RWE is divided into 3 broad categories: macro-, meso-, and micro-RWE; each represents a different quality of evidence and range of use as evidence for HTA. Although typology helps with consolidating RWE choices for supporting HTA decision making, challenges still persist in using it for HTA purposes. Institutional support, technical capacity, and infrastructure, including data-related issues, may hinder progress in improving the RWE ecosystem for HTA in Asia.</div></div><div><h3>Conclusions</h3><div>RWE is a helpful tool that can assist in decision making, especially in reimbursement-related decisions. Although knowing facets of RWE helps in choosing appropriate evidence to assist in policy making, challenges associated with its implementation, especially in the Asian context, need to be anticipated.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101068"},"PeriodicalIF":1.4,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postpartum Screening for Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus: A Cost-Effectiveness Analysis in Singapore 对有妊娠糖尿病史的妇女进行产后 2 型糖尿病筛查:新加坡的成本效益分析。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-30 DOI: 10.1016/j.vhri.2024.101048
Andrea Cremaschi PhD , Willem van den Boom PhD , Nicholas Beng Hui Ng MMed , Beatrice Franzolini PhD , Kelvin B. Tan PhD , Jerry Kok Yen Chan PhD , Kok Hian Tan MMed , Yap-Seng Chong MD , Johan G. Eriksson DMSc , Maria De Iorio PhD

Objectives

In Singapore, diabetes imposes a huge population health and economic burden. Despite that, there is paucity of evidence on the health economics of screening programs for type 2 diabetes, especially in the context of screening after gestational diabetes (GDM). The objective of this study is to assess cost-effectiveness of universal lifelong screening for type 2 diabetes after GDM, which is supported by current guidelines, compared with elective screening where 54% of mothers with GDM undertake one-off screening. Despite the recommendation for universal lifelong screening, only 54% comply with this in the first postpartum year.

Methods

We perform a cost-effectiveness analysis comparing 5 screening strategies, accounting for lifetime costs to the healthcare system and quality of life for Singapore women diagnosed with GDM. In particular, a hybrid decision model, based on a decision tree and Markov models, is implemented to estimate cost and quality-adjusted life-years (QALY). Probabilities, costs, and utilities are obtained from existing literature, governmental databases, the Growing Up in Singapore Towards Healthy Outcomes birth cohort study, and the National University Hospital.

Results

Compared with elective screening, universal annual screening reduces cost by SG$19.4 million while adding 3.8 thousand QALYs by each annual cohort of pregnant women. Furthermore, annual screening is cost-effective (lower cost and higher QALY) compared with triennial screening. Sensitivity analysis shows that the findings are robust to parameter specifications.

Conclusions

Universal annual screening of women with a history of GDM is cost-effective for reducing diabetes complications compared with strategies with less frequent screening in Singapore.
目标:在新加坡,糖尿病给人口健康和经济造成了巨大负担。尽管如此,有关 2 型糖尿病筛查计划的健康经济学证据却很少,尤其是在妊娠糖尿病(GDM)筛查方面。本研究的目的是评估 GDM 后 2 型糖尿病终生筛查与选择性筛查(54% 的 GDM 母亲接受一次性筛查)的成本效益,后者得到了现行指南的支持。尽管建议进行普遍的终身筛查,但在产后第一年只有 54% 的人遵守了这一建议:我们对 5 种筛查策略进行了成本效益分析比较,并考虑了医疗系统的终生成本以及被诊断为 GDM 的新加坡妇女的生活质量。特别是,我们采用了基于决策树和马尔可夫模型的混合决策模型来估算成本和质量调整生命年(QALY)。概率、成本和效用均来自现有文献、政府数据库、新加坡健康成长出生队列研究(Growing Up in Singapore Towards Healthy Outcomes birth cohort study)和国立大学医院:与选择性筛查相比,普及年度筛查可降低成本 1940 万新元,同时每年每批孕妇可增加 380 万个 QALY。此外,与三年一次的筛查相比,每年一次的筛查具有成本效益(成本更低,QALY更高)。敏感性分析表明,研究结果对参数规格具有稳健性:结论:在新加坡,与筛查频率较低的策略相比,每年对有 GDM 病史的妇女进行普遍筛查,对于减少糖尿病并发症具有成本效益。
{"title":"Postpartum Screening for Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus: A Cost-Effectiveness Analysis in Singapore","authors":"Andrea Cremaschi PhD ,&nbsp;Willem van den Boom PhD ,&nbsp;Nicholas Beng Hui Ng MMed ,&nbsp;Beatrice Franzolini PhD ,&nbsp;Kelvin B. Tan PhD ,&nbsp;Jerry Kok Yen Chan PhD ,&nbsp;Kok Hian Tan MMed ,&nbsp;Yap-Seng Chong MD ,&nbsp;Johan G. Eriksson DMSc ,&nbsp;Maria De Iorio PhD","doi":"10.1016/j.vhri.2024.101048","DOIUrl":"10.1016/j.vhri.2024.101048","url":null,"abstract":"<div><h3>Objectives</h3><div>In Singapore, diabetes imposes a huge population health and economic burden. Despite that, there is paucity of evidence on the health economics of screening programs for type 2 diabetes, especially in the context of screening after gestational diabetes (GDM). The objective of this study is to assess cost-effectiveness of universal lifelong screening for type 2 diabetes after GDM, which is supported by current guidelines, compared with elective screening where 54% of mothers with GDM undertake one-off screening. Despite the recommendation for universal lifelong screening, only 54% comply with this in the first postpartum year.</div></div><div><h3>Methods</h3><div>We perform a cost-effectiveness analysis comparing 5 screening strategies, accounting for lifetime costs to the healthcare system and quality of life for Singapore women diagnosed with GDM. In particular, a hybrid decision model, based on a decision tree and Markov models, is implemented to estimate cost and quality-adjusted life-years (QALY). Probabilities, costs, and utilities are obtained from existing literature, governmental databases, the Growing Up in Singapore Towards Healthy Outcomes birth cohort study, and the National University Hospital.</div></div><div><h3>Results</h3><div>Compared with elective screening, universal annual screening reduces cost by SG$19.4 million while adding 3.8 thousand QALYs by each annual cohort of pregnant women. Furthermore, annual screening is cost-effective (lower cost and higher QALY) compared with triennial screening. Sensitivity analysis shows that the findings are robust to parameter specifications.</div></div><div><h3>Conclusions</h3><div>Universal annual screening of women with a history of GDM is cost-effective for reducing diabetes complications compared with strategies with less frequent screening in Singapore.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"45 ","pages":"Article 101048"},"PeriodicalIF":1.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of the Recombinant Zoster Vaccine Among People Living with Human Immunodeficiency Virus in Japan [VHRI Volume 44, November 2024, 101025] 日本人类免疫缺陷病毒感染者接种重组带状疱疹疫苗的成本效益 [VHRI 第 44 卷,2024 年 11 月,101025]
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-29 DOI: 10.1016/j.vhri.2024.101061
So Sato MD, Takaaki Konishi MD, PhD, Hiroyuki Ohbe MD, PhD, Hideo Yasunaga MD, PhD
{"title":"Cost-effectiveness of the Recombinant Zoster Vaccine Among People Living with Human Immunodeficiency Virus in Japan [VHRI Volume 44, November 2024, 101025]","authors":"So Sato MD,&nbsp;Takaaki Konishi MD, PhD,&nbsp;Hiroyuki Ohbe MD, PhD,&nbsp;Hideo Yasunaga MD, PhD","doi":"10.1016/j.vhri.2024.101061","DOIUrl":"10.1016/j.vhri.2024.101061","url":null,"abstract":"","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"44 ","pages":"Article 101061"},"PeriodicalIF":1.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Reform Dynamics of State Management Practices in the Healthcare Sector of the Republic of Kazakhstan: A Global and Local Perspective 哈萨克斯坦共和国医疗部门国家管理实践的改革动力:全球和地方视角。
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-24 DOI: 10.1016/j.vhri.2024.101047
Talgat Zharlygassinov , Rashid Ruzanov PhD , Manshuk Dosmanbetova PhD

Objective

This study aimed to analyze the changes in public administration practices in this area in the Republic of Kazakhstan and to assess the general state of healthcare in the country.

Methods

The study used various methods, including analysis, historical research, deduction, and forecasting, to assess the current state and prospects for healthcare development in the Republic of Kazakhstan and some post-Soviet countries in Eastern Europe.

Results

The findings indicate that although these countries have lower qualitative and quantitative healthcare characteristics than more developed nations, they still outperform Kazakhstan. This suggests that Kazakhstan should take a more proactive approach toward developing its healthcare system and prioritizing the well-being of its citizens, their standard of living, and their ability to combat diseases, including financially.

Conclusions

The article contributes new insights into the healthcare systems of developing countries, including post-Soviet nations.
研究目的本研究旨在分析哈萨克斯坦共和国在这一领域的公共管理实践的变化,并评估该国医疗保健的总体状况:研究采用了分析、历史研究、推理和预测等多种方法,对哈萨克斯坦共和国和东欧一些后苏联国家的医疗发展现状和前景进行了评估:研究结果表明,虽然这些国家在医疗质量和数量方面的特点低于较发达国家,但仍优于哈萨克斯坦。这表明,哈萨克斯坦应采取更加积极主动的方式发展医疗保健系统,优先考虑公民的福祉、生活水平和防治疾病的能力,包括经济方面的能力:文章对发展中国家(包括后苏联国家)的医疗保健系统提出了新的见解。
{"title":"The Reform Dynamics of State Management Practices in the Healthcare Sector of the Republic of Kazakhstan: A Global and Local Perspective","authors":"Talgat Zharlygassinov ,&nbsp;Rashid Ruzanov PhD ,&nbsp;Manshuk Dosmanbetova PhD","doi":"10.1016/j.vhri.2024.101047","DOIUrl":"10.1016/j.vhri.2024.101047","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to analyze the changes in public administration practices in this area in the Republic of Kazakhstan and to assess the general state of healthcare in the country.</div></div><div><h3>Methods</h3><div>The study used various methods, including analysis, historical research, deduction, and forecasting, to assess the current state and prospects for healthcare development in the Republic of Kazakhstan and some post-Soviet countries in Eastern Europe.</div></div><div><h3>Results</h3><div>The findings indicate that although these countries have lower qualitative and quantitative healthcare characteristics than more developed nations, they still outperform Kazakhstan. This suggests that Kazakhstan should take a more proactive approach toward developing its healthcare system and prioritizing the well-being of its citizens, their standard of living, and their ability to combat diseases, including financially.</div></div><div><h3>Conclusions</h3><div>The article contributes new insights into the healthcare systems of developing countries, including post-Soviet nations.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"45 ","pages":"Article 101047"},"PeriodicalIF":1.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of a Specialized Oral Nutritional Supplement in the Management of Chronic Wounds in Patients With and Without Diabetes Mellitus: Cost-Effectiveness Analysis 使用专用口服营养补充剂治疗糖尿病患者和非糖尿病患者的慢性伤口:成本效益分析
IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-24 DOI: 10.1016/j.vhri.2024.101049
Adriano Antonio Mehl MD, MSc, PhD , Victoria Marzagão Ribeiro Pagliosa BSc , Débora Auad Tauil BSc , Valéria Abrahão Schilling Rosenfeld MD

Objectives

To analyze the cost-effectiveness of the use of a specialized oral nutritional supplement (ONS) with proline, arginine, vitamins, and micronutrients to stimulate the healing of chronic wounds in patients with and without diabetes mellitus.

Methods

This is a quantitative study on cost-effectiveness. This model used a decision-tree model followed by a budget impact analysis from the Brazilian public healthcare system’s perspective. For this analysis, the population and data from a randomized trial of an oral specialized-ONS-containing supplement were considered. For budget impact analysis, an epidemiologic approach was used to estimate the eligible population. The eligible population comprised 3 different groups: patients with pressure ulcers, patients with vascular ulcers, and patients with diabetic feet. The budget impact analysis used the results of the cost-effectiveness analysis.

Results

The results demonstrate that the use of specialized ONS, when compared with control ONS, proved to be cost saving (cheaper and more effective), considering the presence of predictive scar factor. The aggregated budget impact analysis results shows that the total reduction of costs after 5 years is USD 332 628 437.00.

Conclusions

The use of a specialized ONS was cost-effective in the healing of chronic wounds, when compared with control. The budget impact analysis showed a significant decrease in costs in a 5-year time horizon for the management of pressure ulcers, vascular ulcers, and diabetic feet.
目的分析使用含脯氨酸、精氨酸、维生素和微量元素的专用口服营养补充剂(ONS)来促进糖尿病患者和非糖尿病患者慢性伤口愈合的成本效益:这是一项关于成本效益的定量研究。该模型采用决策树模型,然后从巴西公共医疗系统的角度进行预算影响分析。在分析过程中,考虑了人口和含特殊ONS口服补充剂随机试验的数据。在进行预算影响分析时,采用了流行病学方法来估算符合条件的人群。符合条件的人群包括 3 个不同的群体:压疮患者、血管性溃疡患者和糖尿病足患者。预算影响分析采用了成本效益分析的结果:结果表明,考虑到存在预测性疤痕因素,使用专用 ONS 与对照 ONS 相比,证明可以节省成本(更便宜、更有效)。综合预算影响分析结果显示,5 年后减少的总费用为 332 628 437.00 美元:与对照组相比,使用专门的 ONS 治疗慢性伤口具有成本效益。预算影响分析表明,在 5 年时间内,压疮、血管溃疡和糖尿病足的治疗成本大幅降低。
{"title":"The Use of a Specialized Oral Nutritional Supplement in the Management of Chronic Wounds in Patients With and Without Diabetes Mellitus: Cost-Effectiveness Analysis","authors":"Adriano Antonio Mehl MD, MSc, PhD ,&nbsp;Victoria Marzagão Ribeiro Pagliosa BSc ,&nbsp;Débora Auad Tauil BSc ,&nbsp;Valéria Abrahão Schilling Rosenfeld MD","doi":"10.1016/j.vhri.2024.101049","DOIUrl":"10.1016/j.vhri.2024.101049","url":null,"abstract":"<div><h3>Objectives</h3><div>To analyze the cost-effectiveness of the use of a specialized oral nutritional supplement (ONS) with proline, arginine, vitamins, and micronutrients to stimulate the healing of chronic wounds in patients with and without diabetes mellitus.</div></div><div><h3>Methods</h3><div>This is a quantitative study on cost-effectiveness. This model used a decision-tree model followed by a budget impact analysis from the Brazilian public healthcare system’s perspective. For this analysis, the population and data from a randomized trial of an oral specialized-ONS-containing supplement were considered. For budget impact analysis, an epidemiologic approach was used to estimate the eligible population. The eligible population comprised 3 different groups: patients with pressure ulcers, patients with vascular ulcers, and patients with diabetic feet. The budget impact analysis used the results of the cost-effectiveness analysis.</div></div><div><h3>Results</h3><div>The results demonstrate that the use of specialized ONS, when compared with control ONS, proved to be cost saving (cheaper and more effective), considering the presence of predictive scar factor. The aggregated budget impact analysis results shows that the total reduction of costs after 5 years is USD 332 628 437.00.</div></div><div><h3>Conclusions</h3><div>The use of a specialized ONS was cost-effective in the healing of chronic wounds, when compared with control. The budget impact analysis showed a significant decrease in costs in a 5-year time horizon for the management of pressure ulcers, vascular ulcers, and diabetic feet.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"45 ","pages":"Article 101049"},"PeriodicalIF":1.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Value in health regional issues
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1